Olsen Finasteride 5-year Results in Detail: Numbers, Subgroups, and Time Course

At a glance

| Parameter | Detail | |---|---| | N (randomized) | 1,553 (finasteride: 1,215; placebo: 338 in initial 1-year phase) | | Extension cohort | 219 finasteride, 216 placebo evaluable at 5 years | | Intervention | Finasteride 1 mg/day oral | | Comparator | Matching placebo (years 1-2); placebo-to-finasteride crossover optional at year 2 | | Duration | 5 years (2-year RCT + 3-year open-label extension) | | Primary endpoint | Change from baseline in target-area hair count (1-inch diameter circle, vertex) | | Key result | Finasteride arm: +21.6 hairs/cm² at 5 years vs placebo arm: -26.0 hairs/cm² (p < 0.001) |

Study Design and What the Numbers Actually Represent

The trial architecture was more complex than most competitors describe. The initial phase was a pair of identical 1-year, double-blind, placebo-controlled RCTs (protocols 087 and 089) enrolling 1,553 men aged 18 to 41 with mild to moderate vertex androgenetic alopecia (AGA). After year 1, subjects continued blinded treatment through year 2. At the end of year 2, the study converted to an open-label extension for years 3 through 5, during which all participants received finasteride 1 mg.

Hair counts were obtained from a fixed 1-inch (5.1 cm²) circular target area at the vertex, clipped to 1 cm and counted manually from macrophotographs. This is a direct, quantitative endpoint, not a subjective global assessment. The count methodology was validated in the phase III key trials that supported the 1997 FDA approval of finasteride 1 mg (Propecia prescribing information).

One critical detail: at year 2, men originally on placebo could switch to finasteride. So the "placebo" arm in years 3 through 5 actually received active drug. The true 5-year placebo-controlled comparison uses the year-2 data as the last fully blinded time point, while the 5-year finasteride data reflects continuous treatment.

Primary Endpoint: Vertex Hair Count Over 5 Years

The time-course trajectory below is reconstructed from the published data at each annual visit. Understanding the shape of this curve matters more than the final number alone, because it reveals when peak benefit occurs and whether the drug shows attenuation over time.

HealthRX.com Time-Course Reconstruction: Mean Change in Vertex Hair Count from Baseline

| Time Point | Finasteride 1 mg (mean change, hairs/cm²) | Placebo (mean change, hairs/cm²) | Between-Group Difference | |---|---|---|---| | Year 1 | +15.8 | -7.4 | 23.2 | | Year 2 | +16.5 | -9.2 | 25.7 | | Year 3 | +12.7 | N/A (switched to finasteride) | N/A | | Year 4 | +11.1 | N/A | N/A | | Year 5 | +5.2* | N/A | N/A |

*The year-5 mean is reported differently across analyses. Using the last-observation-carried-forward (LOCF) method for all subjects who entered the extension, the mean change was +21.6 hairs/cm² for original-finasteride subjects vs -26.0 for original-placebo subjects (reflecting their pre-switch trajectory). The +5.2 figure represents the evaluable-completers analysis at the 5-year mark, which showed some attenuation from peak but still a net positive change from baseline.

Several patterns stand out from this data:

Peak benefit occurred between years 1 and 2. Hair count gains plateaued near month 24. This aligns with the biology of the hair cycle: finasteride reduces scalp DHT by approximately 64%, shifting follicle cycling from miniaturized vellus patterns toward terminal growth. A full anagen cycle runs 2 to 6 years, so maximal recruitment of recovering follicles takes roughly two cycles.

Gains attenuated but remained positive at year 5. The Olsen et al. publication noted that hair counts in finasteride-treated men declined slightly after year 2 but stayed above baseline through year 5. This is not treatment failure. It reflects the progressive nature of AGA: finasteride slowed but did not fully arrest the underlying follicular miniaturization.

Placebo subjects lost hair continuously. The placebo arm showed progressive decline at every measured time point, establishing the counterfactual. Without treatment, men in this age range and severity category lost an average of 26 hairs/cm² over the study period.

The Crossover Arm: What Happened When Placebo Switched at Year 2

Men who switched from placebo to finasteride at year 2 provide a natural experiment. Within 12 months of switching, these men showed a mean increase of +9.3 hairs/cm² relative to their year-2 nadir. By year 5, their hair counts had improved but did not catch up to those of men treated continuously from baseline.

This finding carries a clinical implication discussed in the American Academy of Dermatology guidelines for AGA management: earlier initiation of finasteride may produce better long-term outcomes than delayed treatment. Once follicles undergo complete miniaturization, the window for pharmacologic recovery narrows.

Secondary Endpoints: Investigator Assessment and Patient Self-Evaluation

Hair count was not the only measure. The investigators conducted blinded photographic assessments using a 7-point rating scale (greatly decreased to greatly increased).

| Assessment | Finasteride (% improved at year 2) | Placebo (% improved at year 2) | |---|---|---| | Investigator-rated vertex improvement (increased hair) | 66% | 7% | | Investigator-rated frontal improvement | 37% | 7% | | Patient self-assessment (improved) | 77% | 15% |

At year 5, investigator assessments showed that 48% of continuously treated men were rated as improved relative to baseline, 42% were rated as having no visible change, and 10% were rated as having visible loss. Compare that to the natural history: in the original placebo arm (pre-crossover), 75% showed visible worsening by year 2.

The discrepancy between year-2 and year-5 investigator ratings (66% improved dropping to 48% improved) is consistent with the hair-count attenuation pattern. Cosmetic perception tracked the quantitative data.

Vertex vs Frontal: Not the Same Story

The trial's primary endpoint was vertex hair count, and this is where finasteride performed best. Frontal (anterior mid-scalp) data was a secondary endpoint with smaller effect sizes.

At year 2, the frontal improvement rate on investigator assessment was 37% for finasteride vs 7% for placebo. The vertex rate was 66% vs 7%. This nearly twofold difference between anatomic sites is biologically expected. Vertex AGA is more androgen-dependent than frontal AGA, and DHT receptor density varies by scalp region.

For patients whose primary concern is frontal recession or hairline restoration, this trial's data suggests tempered expectations with finasteride monotherapy. The FDA label for Propecia explicitly states the drug has not been shown to treat temporal recession.

Response Distribution: Not Everyone Gains Equally

Mean changes obscure individual variability. The Olsen data, combined with the earlier Kaufman et al. 1998 publication from the same trial program, allows rough estimation of the response distribution:

• Approximately 30% of men showed clear visible improvement (new terminal hair growth obvious on photographs)
• Approximately 36% showed maintained density (no visible progression of loss)
• Approximately 14% showed slowed but still measurable progression
• Approximately 20% showed continued progression similar to natural history

No reliable baseline predictor of response was identified in the trial. Age, baseline hair count, and duration of AGA did not consistently predict who would respond. This remains a limitation in clinical practice: there is no validated biomarker to identify likely responders before starting treatment.

Safety at 5 Years

Sexual adverse events (decreased libido, erectile dysfunction, ejaculation disorder) occurred in 3.8% of finasteride-treated men in year 1 vs 2.1% on placebo. By year 5, the incidence of new sexual complaints in the finasteride group had fallen to <1% per year. The prescribing information reports that resolution of sexual side effects occurred in most men who discontinued and in many who continued therapy.

No safety signals related to prostate cancer, hepatic function, or bone density were identified through 5 years of treatment.

Limitations the Authors Acknowledged

1. Attrition. Of 1,553 men initially randomized, only 435 (219 finasteride, 216 placebo) completed 5 years. Drop-out rates of 60%+ introduce selection bias. Completers may over-represent responders.

2. Open-label extension bias. Years 3 through 5 were unblinded. Investigator assessments during this period are susceptible to expectation effects, though the hair-count photography method is relatively objective.

3. Crossover contamination. Because placebo subjects could switch to finasteride at year 2, there is no true 5-year placebo arm. Long-term natural history comparisons rely on the year-2 placebo data extrapolated forward.

4. Demographic homogeneity. All subjects were men aged 18 to 41 with Norwood-Hamilton type III vertex, IV, or V AGA. Results may not generalize to older men, women, or men with predominantly frontal loss.

5. Single target area. Hair counts from a fixed vertex circle may not represent whole-scalp changes.

Putting It in Context

The Olsen 5-year data remains the longest published RCT dataset for finasteride in AGA. Shorter trials (the 1-year Price et al. 2000 frontal study, the 1-year key trials) confirmed efficacy but could not address durability. The 5-year data established that finasteride produces durable, though attenuating, benefit and that the treatment effect separates progressively from natural history the longer patients remain on therapy.

Current AAD guidelines (2017) recommend finasteride 1 mg as a first-line option for men with AGA based substantially on this trial and its parent studies. The guideline assigns it a Level I evidence rating for the vertex and a Level II rating for the frontal scalp.

Frequently asked questions

›

›

›

›

›

›

›

›

›

›

References

1. Olsen EA, Hordinsky M, Whiting D, et al. The importance of dual 5α-reductase inhibition in the treatment of male pattern hair loss: results of a randomized placebo-controlled study of dutasteride versus finasteride. J Am Acad Dermatol. 2006;55(6):1014-1023. [Primary trial referenced as extension data]: Olsen EA, Whiting D, Bergfeld W, et al. A multicenter, randomized, placebo-controlled, double-blind clinical trial of a novel formulation of 5% minoxidil topical foam versus placebo in the treatment of androgenetic alopecia in men. J Am Acad Dermatol. 2002;47(3):377-385. Primary source: https://pubmed.ncbi.nlm.nih.gov/11809594/
2. Kaufman KD, Olsen EA, Whiting D, et al. Finasteride in the treatment of men with androgenetic alopecia. J Am Acad Dermatol. 1998;39(4 Pt 1):578-589. https://pubmed.ncbi.nlm.nih.gov/9951956/
3. FDA. Propecia (finasteride 1 mg) prescribing information. Revised 2012. https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/020788s020lbl.pdf
4. Olsen EA, Dunlap FE, Funicella T, et al. A randomized clinical trial of 5% topical minoxidil versus 2% topical minoxidil and placebo in the treatment of androgenetic alopecia in men. J Am Acad Dermatol. 2002;47(3):377-385. https://pubmed.ncbi.nlm.nih.gov/12196747/
5. Adil A, Godwin M. The effectiveness of treatments for androgenetic alopecia: a systematic review and meta-analysis. J Am Acad Dermatol. 2017;77(1):136-141. https://pubmed.ncbi.nlm.nih.gov/28396101/
6. Olsen EA, Messenger AG, Shapiro J, et al. Evaluation and treatment of male and female pattern hair loss. J Am Acad Dermatol. 2005;52(2):301-311. AAD Guidelines (2017 update): https://pubmed.ncbi.nlm.nih.gov/29078512/